Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFACLOR vs ARBLI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Acute otitis media,Acute exacerbations of chronic bronchitis,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Urinary tract infections,Lower respiratory tract infections including pneumonia
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
250-500 mg orally every 8 hours
10 mg orally once daily.
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Hepatic (minor); primarily renally excreted unchanged.
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
25-50% bound to plasma proteins, primarily albumin
>99% bound to albumin and alpha-1-acid glycoprotein.
0.35-0.5 L/kg; distributes into most body tissues and fluids, including middle ear, sinus, and respiratory secretions
0.7 L/kg, indicating extensive tissue distribution.
Oral: 95% well absorbed; food does not significantly affect absorption
Oral: 70% (range 60-80%); IV: 100%.
Cr Cl 10-50 m L/min: 50% of usual dose every 8 hours; Cr Cl <10 m L/min: 50% of usual dose every 12 hours
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
No adjustment required for mild to moderate hepatic impairment; safety in severe impairment not established
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
20-40 mg/kg/day orally divided every 8 hours; maximum 1 g/day
Not established for patients <18 years.
No specific adjustment, but monitor renal function; initiate at lower end of dosing range due to age-related renal decline
No specific dose adjustment required; monitor renal function.
None.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
Hypersensitivity reactions, including anaphylaxis,Clostridium difficile-associated diarrhea,Seizures (especially with renal impairment),Prolonged PT in patients on anticoagulants,False-positive urine glucose test
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Known hypersensitivity to cephalosporins or any component,Previous immediate hypersensitivity reaction to penicillins (cross-sensitivity)
Hypersensitivity to baclofen or any component of the formulation
No significant food interactions; cefaclor can be taken with or without food.,Absorption may be slightly delayed with food but total bioavailability is unaffected.,Avoid grapefruit juice? No known interaction.,Alcohol: No specific interaction, but caution as it may increase side effects like gastrointestinal upset.
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known fetal risks; Cefaclor crosses the placenta with fetal serum concentrations approximately 10-20% of maternal levels.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
Cefaclor is excreted into human breast milk in low concentrations (M/P ratio approximately 0.05-0.10). Considered compatible with breastfeeding by the American Academy of Pediatrics; use with caution in nursing infants with potential for diarrhea or allergic sensitization.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
No dose adjustment required in pregnancy; pharmacokinetic changes (increased volume of distribution, renal clearance) do not necessitate dose modification due to wide therapeutic index.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
Cefaclor is a second-generation cephalosporin with activity against both Gram-positive and Gram-negative organisms, but not Pseudomonas or MRSA.,It is stable against some beta-lactamases, but resistance can occur via extended-spectrum beta-lactamases (ESBLs).,Dose adjustment is required in renal impairment (Cr Cl <40 m L/min).,It is available as an oral suspension and capsules; suspension must be refrigerated and shaken well before use.,Cefaclor may cause a serum sickness-like reaction, especially in children, characterized by rash, arthralgia, and fever.,It has a short half-life (0.6-0.9 hours) and is usually dosed every 8 hours.,Avoid use in patients with immediate hypersensitivity to penicillins due to cross-reactivity risk (about 10%).
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
Take this medication exactly as prescribed, usually every 8 hours, with or without food.,Complete the full course of therapy even if you feel better to prevent bacterial resistance.,Shake the oral suspension well before each dose and refrigerate it; discard any unused portion after 14 days.,Contact your healthcare provider if you develop severe diarrhea, rash, joint pain, or fever.,Inform your doctor if you have a history of allergic reactions to penicillins or cephalosporins.,Do not take this medication if you are allergic to cefaclor or any other cephalosporin antibiotic.,If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
"Phenindione, a vitamin K antagonist anticoagulant, potentiates the effect of cefaclor, a second-generation cephalosporin antibiotic. Cefaclor may reduce vitamin K production by suppressing intestinal flora, thereby enhancing the anticoagulant effect of phenindione. This interaction can lead to an increased international normalized ratio (INR) and risk of bleeding, particularly in patients with poor nutritional status or prolonged antibiotic therapy."
"Dicoumarol may increase the anticoagulant activities of Cefaclor."
"Warfarin may increase the anticoagulant activities of Cefaclor."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEFACLOR vs ARBLI, answered by our medical review team.
CEFACLOR is a Cephalosporin Antibiotic that works by Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.. ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEFACLOR and ARBLI depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEFACLOR is: 250-500 mg orally every 8 hours. The standard adult dose of ARBLI is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEFACLOR and ARBLI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEFACLOR is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third t. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.